Trial Profile
A first-of-its-kind comprehensive clinical study using Stemedica's MCT (Multiple Cell Technology) adult stem cells and the Lumenis SRT laser for the treatment of macular degeneration
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 17 Jun 2014
Price :
$35
*
At a glance
- Drugs Retinal pigment epithelial cell replacement therapy-Stemedica Cell Technologies (Primary)
- Indications Macular degeneration
- Focus Adverse reactions
- 17 Jun 2014 New trial record